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ABSTRACT 
Background: Asthma guidelines guide health practitioners to adjust treatments to the 
minimum level required for asthma control. As many people with asthma have an 
eosinophilic endotype, tailoring asthma medications based on airway eosinophilic levels 
(sputum eosinophils or exhaled nitric oxide, FeNO) may improve asthma outcomes. 
Objective:  To synthesise the evidence from our updated Cochrane systematic reviews, for 
tailoring asthma medication based on eosinophilic inflammatory markers (sputum analysis 
and FeNO) for improving asthma-related outcomes in children and adults. 
Data sources: Cochrane reviews with standardised searches up to February 2017. 
Study selection: The Cochrane reviews included randomised controlled comparisons of 
tailoring asthma medications based on sputum analysis or FeNO compared to controls 
(primarily clinical symptoms and/or spirometry/peak flow).  
Results: The 16 included studies of FeNO-based management (7 in adults) and 6 of sputum-
based management (5 in adults) were clinically heterogeneous. On follow-up, participants 
randomised to the sputum eosinophils strategy (compared to controls) were significantly less 
likely to have exacerbations (62 vs 82/100 participants with ≥1 exacerbation; OR=0.36, 
95%CI 0.21 to 0.62). For the FeNO strategy, the respective numbers were; adults OR=0.60, 
95%CI 0.43 to 0.84 and; children 0.58 (95%CI 0.45 to 0.75). However, there were no 
significant group differences for either strategy on daily inhaled corticosteroids dose (at end 
of study), asthma control or lung function.  
Conclusion:  Adjusting treatment based on airway eosinophilic markers reduced the 
likelihood of asthma exacerbations but had no significant impact on asthma control or lung 
function. 
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What is the key question? 
What is the overall outcome of trials that utilise eosinophilic markers (sputum eosinophil 
counts or exhaled nitric oxide levels, FeNO) to tailor asthma treatment in children and adults? 
 
What is the key point? 
Treatment tailored using eosinophilic markers results in fewer asthma attacks when compared 
to traditional management but did not impact on day-to-day reported symptoms, lung 
function or final daily inhaled corticosteroid doses. 
 
Why read on? 
This systematic review combines 3 Cochrane reviews with 22 included studies, examining 
the updated evidence for objectively measuring inflammatory markers to personalise asthma 
management. 
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INTRODUCTION 
The main aim of asthma guidelines is to provide an evidence-based approach to assist health 
professionals improve their patients’ asthma management, which involve using the minimal 
amount of medications to optimize asthma outcomes (minimal symptoms and exacerbations 
and high quality of life).1-3 Exacerbations are important as they cause anxiety to patients and 
are associated with increased healthcare cost.4 Monitoring asthma control is important in 
asthma management, although there is no single outcome measure that can adequately assess 
asthma control.5 Subjective measures usually involve a series of questions used for clinical 
assessment, and can include diary cards and quality of life (QoL) questionnaires. Traditional 
objective methods used to monitor asthma (but not control) include indices of 
spirometry/peak flow and airway hyperresponsiveness.6 Newer methods include 
measurement of airway inflammation, such as airway cellularity in induced sputum or 
fractional exhaled nitric oxide (FeNO), as pheno/endotypes of asthma are increasingly 
appreciated.7  
 
The inflammation in airways of people with asthma can be predominantly eosinophilic or 
non-eosinophilic (including neutrophilic).8 Irrespective of the type of airway inflammation, 
inhaled corticosteroids (ICS) remain the major preventer therapy to control asthma 
symptoms, other than for children with mild intermittent asthma.2 However ICS are more 
effective in reducing symptoms in patients with eosinophilic inflammation than those with 
neutrophilic inflammation.9 Thus, treatment tailoring based on objective eosinophilic 
inflammation data may be helpful in improving asthma outcomes. Currently clinically 
available techniques are assessing airway cellularity and FeNO.10 
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The increased attention to personalised medicine, which for asthma includes basing treatment 
on objective airway inflammation11 is reflected by interest in our previous systematic review 
.12 We present an update to our previous review12 by providing an overview of three recent 
related Cochrane reviews,13-15 each of which addressed a different question as per the PICO 
framework. The objective of our systematic review is to evaluate the efficacy of tailoring 
asthma medications based on FeNO or sputum eosinophils (i.e. eosinophilic-based strategy) 
in comparison to controls (clinical symptoms with or without spirometry/peak flow) for 
asthma-related outcomes in children and adults.  
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METHODS  
Inclusion criteria, outcomes and analyses were a-priori specified and documented in 
Cochrane review protocols and in the first versions of the three reviews on The Cochrane 
Library.13-15 
 
Eligibility, Information Sources, Search Strategy and Study Selection 
We used Cochrane methods and searched (up to February 2017) for eligible randomised 
controlled trials (RCTs) that compared adjustment of asthma medications based on sputum 
eosinophils or FeNO levels with adjustment according to clinical symptoms (with or without 
spirometry/peak flow). As outlined in the reviews,13-15 searches used keywords in electronic 
sources (Cochrane Airways Group Specialised Register of Trials, the Cochrane Central 
Register of Controlled Trials (CENTRAL), Medline, EMBASE) and reference hand 
searching. Searches of bibliographies and texts were conducted to identify additional studies. 
Trials that included the use of other interventions were included if all participants had equal 
access to such interventions.  
 
Participant inclusion criteria were children and adults with a diagnosis of asthma according to 
a guideline-defined criteria. Exclusion criteria were as follows: eosinophilic bronchitis, 
asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive 
airway disease, or diagnostic categories such as 'cough variant asthma' and 'wheezy 
bronchitis' where controversies exist. 
 
Data extraction  
Titles and abstracts of all records returned by the literature search were reviewed 
independently in duplicate to identify potentially relevant trials. Searches of bibliographies 
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and texts were conducted to identify additional studies. Using the pre-specified criteria, two 
reviewers independently reviewed full texts to select trials for inclusion. There was no 
disagreement although it was planned that disagreement would have been resolved by third 
party adjudication. We extracted information from each trial on (a) study characteristics, (b) 
intervention type, and (c) outcomes, as described in our Cochrane reviews.13-15  
 
Risk of bias  
Risk of bias for each included study was assessed using the Cochrane Risk of Bias tool 
available in the RevMan5 software. Seven components were assessed in duplicate as low, 
unclear or high risk of bias: Sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete outcome data, 
selective reporting and other bias. 
 
Summary (outcome) measures  
Primary outcomes were indices reflective of asthma exacerbations (defined by study authors) 
during the follow-up period. Secondary outcomes were mean differences (MD) between 
groups in objective measurements of asthma (FEV1, peak flow, airway hyper-
responsiveness), FeNO level, symptoms of asthma (as reported in Asthma Control Test 
(ACT) or asthma-related QoL score) and ICS dose at final visit. 
 
Methods of analyses  
The results from studies that met the inclusion criteria and reported any of the outcomes of 
interest were included in the subsequent meta-analyses. We a-priori separated children from 
adult studies. All data were double entered (HP/AC or HP/KK) and triple checked (CC). We 
combined data for meta-analyses only where it was meaningful (i.e. based on clinical and 
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statistical criteria). We analysed dichotomous data as odds ratios (OR) and continuous data as 
MD, or as standardised mean difference (SMD) if different measurement scales were used 
across studies. For dichotomous data, we reported the proportion of participants contributing 
to each outcome in comparison with the total number randomised. Generic inverse variance 
was used for rate ratio (RR) analysis of common events, whereby one subject may have more 
than one event. The RRs were taken from the published papers and standard errors (SE) of 
the Log RR were calculated from confidence intervals (CI) or P-values published in the 
papers. Numbers needed to treat (NNT) were calculated from the pooled OR and its 95%CI 
applied to a specified baseline risk using an online calculator.16 Fixed effects were used 
throughout unless stated otherwise. 
Any heterogeneity between the study results was described and tested to see if it reached 
statistical significance using a chi-squared test. We included the 95%CI estimated using a 
random effects model whenever there were concerns about statistical heterogeneity. 
Heterogeneity was considered significant when the P value was <0.10.17 We used the I2 
statistic to measure heterogeneity among the trials in each analysis. If we identified 
substantial heterogeneity (>50%), we reported it and explored possible causes. Subgroup 
analysis was planned for: 1. Basis for adjustment of ICS in the control group (guideline-
driven monitoring versus non-guideline driven); 2. Use of spirometry or peak flow as an 
adjunctive monitoring tool for adjustment of medications (versus non-use of spirometry or 
peak flow); 3. Baseline ICS dose at commencement of intervention (<800 mcg/day versus 
>800 mcg/day budesonide equivalent); 4. Cut-offs for adjustment of medications. 
We used the five GRADE considerations (study limitations, consistency of effect, 
imprecision, indirectness and publication bias) to assess the quality of a body of evidence as 
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it relates to the studies that contributed data to the meta-analyses for the pre-specified 
outcomes. 
RESULTS 
Study selection and study characteristics 
The searches in 2017 identified 1208 publications for FeNO-based strategy and 1213 for 
sputum. After screening, 30 and seven papers respectively were retrieved but only 16 and six 
respectively fulfilled the inclusion criteria (Figure-1), including the nine studies from the 
previous review.12 The 22 studies consisted of 16 FeNO-based trials (7 adults, 9 children) and 
six sputum-based trials (5 adults, 1 children), which included a total of 3500 participants, of 
whom 3208 completed the studies (91.7%). 
 
Of the 22 studies included (Table 1, Supplement Table-1), nine were single centre studies,18-
26 two were dual-centred27, 28 and 11 were multi-centred.29-39 Ten studies were in children or 
adolescents,18, 19, 20, 26, 28-30, 32-34 and twelve involved adult participants.21-25, 27, 31, 35-39  We 
classified studies into children/adolescent studies based on the mean age reported as opposed 
to the entry criteria. Nine studies were double-blind, parallel group trials, 18, 24, 26-29, 31, 32, 35 
seven were single-blind, parallel group trials,19, 21, 22, 25, 33, 34, 38 and six studies had no 
blinding.20, 23, 30, 36, 37, 39 Twenty-one papers were published in English and one was translated 
from Chinese.22 Seven studies were supported by Aerocrine, the manufacturer of FeNO 
analyser (Supplement Table-1). 
 
Table 1: Characteristics of included studies
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Study Sample size Description of intervention and control arms 
Calhoun 
201235 
FeNO group 
N=115. 
Control group 
N=114. 
Control group: National Heart, Lung and Blood Institute 
guidelines. 
FeNO group: <22ppb treatment stepped down 
22 to 35 maintain treatment 
>35 increase treatment 
Cao 200722 EOS strategy 
N=20. 
Control group 
N=21. 
Control strategy: “Standard clinical guidelines” 
EOS strategy: decrease ICS <1% eosinophils, keep ICS the same 
1-3% eosinophils, increase ICS if eosinophils >3%. 
Chlumsky 
200623 
EOS strategy 
N=30. 
Standard 
strategy N=25. 
Standard strategy arm: GINA guidelines 
EOS strategy: decrease ICS if ≤3%, keep same if 4-8%, increase 
ICS if ≥8%. 
deJongste 
200930 
FeNO group 
N=75. 
Symptom group 
N=72. 
All participants scored asthma symptoms in an electronic diary 
over 30 weeks. Aim to keep FeNO <20ppb 
Symptom group based on symptom score: Below range (< 10) = 
step down/discontinue, range 10 to 60 = no change and range > 
60 = step up 
Fleming 
201226 
Inflammatory 
group N=27. 
Symptom group 
N=28. 
Symptom group: Based on number of major exacerbations in the 
preceding 3 months and SABA use in preceding 2 weeks. 
Inflammatory group: Treatment aimed to keep sputum eosinophil 
counts <2.5%. 
Fritsch 
200619 
FeNO group 
N=22. 
Control group 
N=25. 
FeNO group: therapy was based on symptoms, beta-agonists use, 
lung function and FeNO. 
Control group: therapy based on symptoms, beta-agonists and 
lung function only. 
Green 
200224 
Sputum 
management 
group N=37. 
BTS group 
N=37. 
Sputum management group: anti-inflammatory treatment was 
based on maintenance of sputum eosinophil count below 3% 
with a minimum dose of anti-inflammatory treatment. 
BTS management group: BTS/SIGN guidelines. 
 
Hashimoto 
201136 
Internet strategy 
N=51. 
Conventional 
strategy N=38. 
Internet strategy: Had steroid dose adjusted based on the 3 
components: electronic diary, in-built algorithm (which includes 
FeNO levels), and monitoring support. 
Conventional strategy: GINA guidelines for the treatment of 
severe asthma. 
Honkoop 
201437 
FeNO group 
N=189. 
Controlled 
asthma group 
N=203. 
Cluster randomization (at general practice level). 
FeNO strategy: Treatment targeted to keep FeNO <50ppb. 
Symptom strategy: ACT utilized including lung function 
Jayaram 
200631 
Sputum strategy 
group N=50. 
Sputum strategy: Guided solely by induced sputum eosinophils 
to keep <2%. 
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Clinical strategy 
group N=52. 
Clinical strategy: Canadian Asthma Consensus Group 
Guidelines. 
Malerba 
201525 
Sputum strategy 
N=14. 
Clinical strategy 
N=14. 
Sputum strategy: Treatment based on sputum eosinophil (%) and 
FeNO (ppb). 
Decrease ICS <2% & ≤10pbb 
Keep same 2-3% & 11-20ppb 
Increase ICS >3% & ≥20ppb 
Symptom strategy: Symptom scores, use of SABA and night 
time symptoms. 
Peirsman 
201434 
FeNO group 
N=49. 
Control group 
N=50. 
FeNO group: Treatment aimed to keep FeNO below 20ppb. 
Control group: GINA guidelines 
Petsky 
201528 
FeNO group 
N=31. 
Symptom group 
N=32. 
FeNO group: Treatment adjusted based on FeNO level and atopy 
status. Elevated FeNO defined as: 
≥ 10ppb with no positive SPT 
≥ 12ppb with 1 positive SPT 
≥ 20ppb with ≥ 2 positive SPT 
Control group: Symptom diary cards 
Pijnenburg 
200518 
FeNO group 
N=39 
Symptom group 
N=46 
FeNO group: FeNO guided ICS dosing according to 
predetermined algorithm. 
Symptom group: Symptom scores influenced ICS dosing. 
Pike 201332 FeNO group 
N=44. Standard 
management 
group N=46. 
FeNO group: FeNO measurements and symptom control. 
Standard management group: symptom control as per blinded 
clinician (reliever use, FEV1). 
 
Powell 
201127 
FeNO group 
N=111. 
Control group 
N=109. 
FeNO group: Sequential process, first FeNO concentrations used 
to adjust ICS dose, and second ACT score used to adjust the 
LABA dose. 
Clinical group: Juniper ACT cutoff points defined as: well-
controlled asthma (ACT < 0.75), partially controlled asthma 
(0.75 to 1.50), and uncontrolled asthma (> 1.5) 
Shaw 
200738 
FeNO group 
N=58 
Control group 
N=60. 
FeNO group: FeNO >26ppb, ICS was increased. If FeNO 
<16ppb or <26ppb on 2 separate occasions, treatment was 
decreased. 
Control Group: Treatment was doubled if Juniper Asthma 
Control Score (JACS) >1.57 and treatment halved if JACS <1.57 
for 2 consecutive months. 
Smith 
200521 
97 patients 
randomised 
from 110 
patients 
FeNO group: Based to keep FeNO <15ppb at 250mL/sec. 
Control group: dose adjustment based on asthma symptoms, 
night-time waking, bronchodilator use, variation in PEFR and 
FEV1. 
Syk 201339 FeNO group 
N=87. 
Control group 
N=78. 
FeNO group: Keep FeNO level <24ppb for women, and <26ppb 
for men. 
Control group: Treatment adjusted based on patient reported 
symptoms, SABA use, physical examination and spirometry 
results. 
Szefler 
200829 
FeNO group 
N=276. 
FeNO group: Standard treatment modified on the basis of 
measurements of FeNO 
 13 
 
 
 
Control group 
N=270 
Control group: National Asthma Education and Prevention 
Program (NAEPP) guidelines 
Verini 
201020 
FeNO group 
N=32. GINA 
group N=32. 
FeNO group at 6 month visit only: step treatment up if >12ppb. 
Control group: GINA guidelines. 
Voorend-
van Bergen 
201533 
FeNO group 
N=92. 
Standard care 
group N=89. 
FeNO group: Treatment adjusted according to FeNO levels and 
ACT results. If ACT ≥ 20 and: 
FeNO < 25 = step down 
FeNO ≥ 25 to < 50 = no change 
FeNO ≥ 50 = step up 
If ACT < 20 and: 
FeNO ≥ 25 = step up 
FeNO < 25 = no change 
Control group: Treatment adjusted based on ACT results 
< 20 = step up 
≥ 20 = no change or step down 
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There was a degree of clinical heterogeneity among the studies (Table-1, Supplement Table-
1), primarily with regard to the definition of an asthma exacerbation and the FeNO and 
sputum eosinophil cut-offs used for adjusting therapies. Although asthma exacerbations were 
an outcome measure in all papers, they differed in how they were defined ranging from 
unscheduled emergency visits25 to defining an exacerbation using diary card data.21, 28 Two 
studies defined an exacerbation as a decrease in morning lung function.24, 36 Although there 
were variations in how exacerbations were defined, all included studies uniformly managed 
exacerbations with rescue oral steroids. Algorithms for adjustment of medications differed 
among studies and the cut-off values to step-up and down also varied across the FeNO studies 
(range 1220, 28 to 50ppb37), and the sputum eosinophil percentages (range from 231 to 823).  
 
Outcomes and synthesis of results 
Primary (Exacerbations) 
In both adults and children, the number of participants with exacerbations (during the follow-
up period 18-52 weeks) in the group whose treatment was adjusted according to FeNO were 
significantly lower than the control group; in adults OR was 0.60 (95%CI 0.43, 0.84, p=0.003; 
participants=1005; studies=5) and in children the OR was 0.58 (95%CI 0.45, 0.76, p<0.0001; 
participants=2284; studies=8) (Figure-2). Based on the number of participants who had at 
least one exacerbation over the study period (Table-2), the number to treat to benefit (NNTB) 
over 52 weeks was 12 (95%CI 8, 32) in adults; and 9 (95%CI 6, 15) in children. 
 
Table 2: Number of participants who had ≥1 exacerbation over the study period 
 
Adult studies 
FeNO group 
 
Control group 
 
N with 
exacerbation 
N of group N with 
exacerbation 
N of group 
       Honkoop 2014 23 189 30 203 
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       Powell 2011 28 111 45 109 
       Shaw 2007 12 58 19 60 
       Smith 2005 14 46 11 48 
       Syk 2013 15 93 25 88 
 
Paediatric studies 
  
       de Jongste 2008 9 75 12 72 
       Peirsman 2014 11 49 22 50 
       Petsky 2015 6 31 15 32 
       Pijnenburg 2005 7 42 10 47 
       Pike 2013 37 44 38 46 
       Szefler 2008 91 276 115 270 
       Verini 2010 16 32 26 32 
       Voorend-van Bergen 2015 9 92 14 89 
 
The exacerbation rate in the FeNO-strategy group was significantly lower than controls in the 
adult studies (RR=0.59, 95%CI 0.45, 0.76; participants=842; studies=5). There was no 
significant difference between groups in the paediatric data and as statistical heterogeneity 
among studies was present, we used random effects analysis to calculate the rate of 
exacerbations over 52 weeks (MD =-0.37, 95%CI -0.8, 0.06; participants=736; studies=4). 
 
In the sputum-based meta-analysis (Figure-3), significantly fewer adults and children in the 
sputum-based strategy had asthma exacerbations compared to the control group (73 vs 100; 
p=0.0002), OR 0.36 (95%CI 0.21, 0.62); participants=173; studies=4. The NNT for one 
participant (adults) to avoid any exacerbations was 5 (95%CI 4, 11) over 16 months. 
 
Secondary Outcomes 
Inhaled Corticosteroid (ICS) Dose 
For the FeNO-based studies, the meta-analysis found no significant group differences in the 
final ICS dose for adults or children (Figure-4). In adults, the direction favoured the FeNO 
strategy (MD between groups was -147.15ug budesonide equivalent; 95% CI -380.85, 86.56; 
p=0.22; participants=582; studies=4) but the direction in children favoured the control 
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strategy (MD 65.88ug budesonide equivalent, 95%CI -86.71, 218.47; p=0.40; 
participants=317; studies=3) (Figure-4).  
 
All five studies that utilised sputum eosinophils to adjust treatment reported no differences in 
doses of ICS used between groups (Supplement Figure-1). The SDs for the groups were not 
available in Jayaram et al’s paper31 and were estimated based on the data from Green’s 
paper.24 The mean dose of ICS per person per day (ug budesonide equivalent) between groups 
was non-significant in adult studies, (MD 0.67, 95%CI -154.39, 155.73; p=0.99; 
participants=262; studies=4). Likewise, there was no difference in daily ICS doses in the sole 
paediatric study (MD 67.0, 95%CI -264.81, 398.81; p=0.69; participants=54). 
 
Symptom scores and other outcomes 
Symptom or ACT scores did not significantly differ between groups for FeNO-studies in 
either adults or children (Supplement Figure-2). In adults (4 studies), the direction of the 
difference in scores favoured the FeNO strategy, mean difference was -0.08 (95%CI -0.18, 
0.01; p=0.09; participants=707) but the direction in children favoured the control group: mean 
difference was 0.14 (95%CI -0.18, 0.47; p=0.39; participants=724; studies=2). For the 
sputum-based studies, the two studies that reported on symptom scores also described no 
significant difference in symptoms scores between groups.23, 24 Likewise for the outcome of 
asthma QoL scores, there were no significant group differences for the FeNO-based studies in 
adults and children (Supplement Figure-3). In adults, there were only two studies and the 
mean difference in children was 0.09 (95%CI -0.08, 0.26; p=0.29; studies=3). 
 
There was insufficient data reported from the individual studies to undertake a meta-analyses 
for the other secondary outcomes (FEV1, AHR, rescue B agonist use). While FEV1 was 
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reported in all studies, data points were not provided; the studies described they found no 
difference between the participants who had treatment adjusted to inflammatory markers in 
comparison to the control group.  
 
Subgroup analyses 
As per Table 1, eight of the 16 FeNO-based studies20, 21, 29, 32, 34-36, 38 utilised guideline-driven 
monitoring for the control group. In this subgroup analysis based on trials that utilised 
guideline driven monitoring, the significant difference was no longer present for the primary 
outcome of number of participants who had one or more exacerbations (OR 0.87, 95%CI 
0.47, 1.61) in adults (4 studies) but that in children (4 studies) still significantly favoured the 
FeNO strategy (OR 0.67, 95%CI 0.51, 0.90). The subgroup analyses results for ‘cut-off FeNO 
values’ were similar to the main analyses; the FeNO group had significantly fewer 
exacerbations. As there was insufficient data, we could not undertake subgroup analyses for 
the other planned sub-groups. 
 
Risk of bias in individual studies 
The risk of bias diagram (Figure 5) shows that eight studies18, 24-28, 31, 34, 38 were judged as 
having good methodological quality, but in all studies there was either insufficient details 
about allocation concealment and/or adequacy of blinding. Seven studies20, 23, 30, 33, 36, 37, 39 
were open label or single blinded (6 in FeNO studies, 1 in sputum driven studies). When data 
from the six open label FeNO driven studies20, 30, 33, 36, 37, 39 were removed, the primary 
outcome results (exacerbations) did not change. In adults, the number of participants who had 
one or more exacerbations over the study period OR=0.63 (95%CI 0.41, 0.96; 
participants=432; studies=3) and exacerbation rates (RR=0.61, 95%CI 0.45, 0.82; 
participants=661, studies= 4). In children, the number of participants who had one or more 
 18 
exacerbations over the study period OR=0.67 (95%CI 0.50, 0.89; participants=887, 
studies=5). 
 
One sputum eosinophil driven study23 did not use blinding, however removing the datum 
from this study did not alter the results of the primary outcome (exacerbations); occurrence of 
any exacerbation (RR 0.66, 95%CI 0.46, 0.93; participants=218; studies=3), or number of 
participants who had one or more exacerbations over the study period (OR 0.43, 95%CI 0.24, 
0.79; participants=218; studies=3). 
 
For the FeNO-based adult papers, the quality of evidence using the GRADE approach 
surmises that, of the three outcomes assessed, two were of moderate quality and one (ICS 
dose at final visit) was very low quality due to wide confidence intervals and the fact that one 
study39 was open labelled, as well as heterogeneity between doses (Table 3). For the FeNO-
based children studies, the quality was moderate for two outcomes and very low for one 
(exacerbation rates). This outcome was downgraded three levels for one open labelled study, 
20 imprecision and heterogeneity (I2=67%) (Table 4). For sputum-based studies, GRADE 
assessment shows that the quality of the three outcomes were moderate for two outcomes 
(exacerbations) and low (ICS dose) due to the lack of blinding in one study,23 and the varied 
doses within and between studies (Table 5).  
Table 3: Summary of findings for the main comparisons: FeNO based adult studies 
Tailoring asthma treatment using FeNO versus clinical symptoms 
Patient or population: Adults with asthma 
Setting: outpatient 
Intervention: asthma treatment tailored on FeNO 
Comparison: asthma treatment tailored on clinical symptoms 
Outcomes 
Anticipated absolute 
effects* (95% CI) 
Relative 
effect 
(95% 
CI) 
№ of 
participants 
(studies) 
Quality of the 
evidence 
(GRADE) Comments 
Risk with 
asthma 
Risk with 
asthma 
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treatment 
tailored on 
clinical 
symptoms** 
treatment 
tailored 
on FeNO 
Number of 
participants 
who had ≥ 1 
exacerbations 
over study 
period 
Follow-up: 
range 18 
weeks to 52 
weeks 
25 per 100 17 per 
100 
(13 to 22) 
OR 0.60 
(0.43 to 
0.84) 
1005 
(5 RCTs) 
⊕⊕⊕⊝ 
MODERATE1 
- 
Number of 
exacerbations 
per 52 weeks 
(exacerbation 
rates) 
Follow-up: 
mean 52 
weeks 
The control 
group ranged 
from 0.23 to 
0.9 
exacerbations 
per 52 weeks 
Rate ratio 
0.59 (0.45 
to 0.77) 
- 842 
(5 RCTs) 
⊕⊕⊕⊝ 
MODERATE1 
- 
ICS dose at 
final visit 
Follow-up: 
range 18 
weeks to 52 
weeks 
The mean 
ICS dose 
taken by the 
control group 
at final visit 
was 
659 mcg 
The mean 
ICS dose 
taken in 
the FeNO 
groups 
was 17.01 
lower 
(101.75 
lower to 
67.72 
more) 577 
mcg 
- 582 
(4 RCTs) 
⊕⊕⊝⊝ 
VERY 
LOW2,3 
A random-
effects 
sensitivity 
analysis 
gave a very 
imprecise 
result: MD 
-147.15 
(95% CI -
380.85 to 
86.56) 
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). 
**The control group risks were calculated as a mean of the scores or events in the control 
groups of the studies contributing to each analysis. We could not calculate a control risk for 
the number of exacerbations per 52 weeks because we did not have information for each arm 
of the studies, just ratios between them. 
CI: confidence interval; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroids; 
MD: mean difference; OR: odds ratio; RCT: randomised controlled trial 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of 
the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
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Low quality: Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is 
likely to be substantially different from the estimate of effect 
 
Table 4: Summary of findings for the main comparisons: FeNO based paediatric studies 
Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms 
Patient or population: Children with asthma 
Setting: outpatient 
Intervention: asthma treatment tailored on FeNO 
Comparison: asthma treatment tailored on clinical symptoms 
Outcomes Anticipated absolute 
effects* (95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments 
Risk with 
clinical 
symptoms 
Risk with 
asthma 
treatment 
tailored on 
FeNO 
Number of 
participants 
who had ≥ 1 
exacerbations 
over study 
period 
(48.5 weeks) 
40 per 100 28 per 100 
(23 to 33) 
OR 0.58 
(0.45 to 
0.75) 
1279 
(8 RCTs) 
⊕⊕⊕⊝ 
Moderate1 
- 
Number of 
asthma 
exacerbations 
per 52 weeks 
(exacerbation 
rate) 
The mean 
number of 
asthma 
exacerbations 
per 52 weeks 
(exacerbation 
rate) was 1.66 
The mean 
number of 
asthma 
exacerbations 
per 52 weeks 
(exacerbation 
rate) in the 
intervention 
group was 
0.37 lower 
(0.8 lower to 
0.06 higher) 
MD -
0.37 (-
0.8 to 
0.06) 
736 
(4 RCTs) 
⊕⊝⊝⊝ 
Very low2 
- 
ICS dose at 
final visit 
(budesonide 
equivalent) 
The mean ICS 
dose at final 
visit 
(budesonide 
equivalent) 
was 483 
μg/day 
The mean ICS 
dose at final 
visit 
(budesonide 
equivalent) in 
the 
intervention 
group was 
- 317 
(3 RCTs) 
⊕⊕⊕⊝ 
Moderate3 
- 
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63.95 μg/day 
higher (51.89 
lower to 
179.79 higher) 
*The risk in the intervention group (and its 95% confidence interval) is based on the 
assumed risk in the comparison group and the relative effect of the intervention (and its 
95% CI). 
 
CI: confidence interval; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroid; 
MD: mean difference; OR: odds ratio; RCT: randomised controlled trial 
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Table 5: Summary of findings for the main comparisons: Sputum eosinophilia based studies 
Tailored interventions based on sputum eosinophils compared to tailored interventions 
based on clinical symptoms for asthma in adults and children 
Patient or population: Adults and children with asthma 
Settings: hospital outpatients 
Intervention: based on sputum eosinophils count 
Comparison: based on clinical symptoms 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments 
Assumed 
risk at one 
year 
Corresponding 
risk 
Tailored 
interventions 
based on 
clinical 
symptoms 
Tailored 
interventions 
based on 
sputum 
eosinophils 
Number of 
participants 
who had one or 
more 
exacerbations 
over the study 
period 
Follow-up: 12 to 
24 months 
82 per 100 62 per 100 
(49 to 74) 
OR 0.36  
(0.21 to 
0.62) 
228 
(3 studies) 
⊕⊕⊕⊝ 
moderate1 
 
Hospitalisations 
Follow-up: 12 to 
24 months 
24 per 100 8 per 100 
(3 to 21) 
OR 0.28  
(0.09 to 
0.84) 
269 
(4 studies) 
⊕⊕⊕⊝ 
moderate2 
 
Mean dose of 
inhaled 
corticosteroids 
per person per 
day (BUD 
equivalent 
mcg/day) 
Follow-up: 12 to 
24 months 
 
The mean dose 
of inhaled 
corticosteroids 
per person per 
day in the 
intervention 
groups was 
13 mcg/day 
higher 
(128 lower to 
153 higher) 
 
316 
(4 studies) 
⊕⊕⊝⊝ 
low3 
 
*The basis for the assumed risk is the mean of the two studies with a duration of one year. The 
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; OR: Odds ratio; 
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DISCUSSION 
In this meta-analysis, we combined data from our 3 Cochrane reviews13-15 that evaluated the 
efficacy of tailoring asthma medications (ICS predominantly) based on airway eosinophilic 
markers (FeNO or sputum eosinophils) in comparison to controls (clinical symptoms with or 
without spirometry/peak flow) for asthma-related outcomes in children and adults. Based on 
twenty-two studies involving 3500 adults and children (3208 completed), we found that 
children and adults randomised to either eosinophilic marker strategy (compared to controls) 
were significantly less likely to experience an exacerbation during the follow-up period (4.5-
24 months). The exacerbation rate was also significantly lower in adults randomised to the 
FeNO or sputum strategy (compared to controls) but not in children. There was not a 
significant difference in the final dose of ICS in either children or adults.  For both FeNO and 
sputum-based strategies, there was no difference between groups for all secondary outcomes 
(FEV1, ACT, QoL, airway hyper-responsiveness or beta2-agonist use). 
 
In this review updated from our previous combined meta-analyses,12 the data on sputum 
remained unchanged, i.e.  using sputum to guide asthma therapies in adults is beneficial for 
the outcome of reducing exacerbations. The new single paediatric study26 found no significant 
difference between the groups for this outcome, although favoured the sputum-based strategy. 
However, the OR for the combined adult and paediatric studies remained unchanged at 0.36 
but the 95%CI was marginally smaller from 0.20 to0.64 to 0.21to 0.62.  
 
In contrast to the data for sputum, the additional 10 studies included in the FeNO strategy 
analyses altered the previous ‘no benefit’ found in our previous review12 to ‘some benefit’ as 
using a FeNO-based strategy reduced the number of participants with asthma exacerbations 
during the follow-up period in both children and adults.  However, the benefit was 
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inconsistent as there was no longer any significant difference between groups in the 
sensitivity analyses for adults, whilst in children there was no group differences for 
exacerbation rate.  While this new data is somewhat supportive of authors who previously 
advocated using FeNO levels to tailor medications,40 we do not believe there is currently 
sufficient evidence to universally use FeNO to monitor airway inflammation recommended 
by others.41  
 
In contrast to the favourable data in the outcome of exacerbations for both sputum and FeNO- 
based strategies, the data for other asthma outcomes (FEV1, symptom scores, QoL and beta2 
agonist use) remained unchanged i.e. neither sputum and FeNO- based strategies were shown 
to confer any advantage over the control arms. There may be several reasons for this 
including the known discordance between asthma control and exacerbations.1 While 
exacerbations are an important outcome, arguably subjective measures of asthma control are 
also important. Thus, although our findings demonstrate that using airway eosinophilic 
markers to guide medications future exacerbations, it is debatable whether either strategy 
should be universally advocated. Sputum analysis is restricted to laboratories with specific 
expertise, is relatively time consuming and is not always successful, particularly in young 
children. Use of FeNO universally will add a substantial cost to the millions of people who 
have asthma. Also, currently there is no evidence-based algorithm on how to adjust treatment 
based on FeNO levels (or indeed to sputum eosinophils levels) and the various guidelines 
(such as GINA1, BTS2, NAC3) differ on when and how to step up and down asthma therapies.  
Nevertheless, using airway eosinophilic markers to guide asthma therapy is most likely to be 
beneficial to the subset of people with frequent asthma exacerbations. 
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The data on the FeNO-based studies also need to be considered in light of several issues. 
Firstly, only one28 of the 16 included studies utilising FeNO considered presence or severity 
of atopy in their algorithm of management although some but not all subjects were atopic. 
FeNO is higher when eosinophilic inflammation is present, however it is also higher in other 
conditions (eg. atopy, allergic rhinitis, eczema).1 Secondly, the cut offs of FeNO utilised for 
stepping up or down therapy differed between studies (range 15-50 ppb). Pijnenburg et al18 
(paediatric study) subjects had the highest mean daily dose of ICS and subjects in this study 
also had quite high FeNO at the final visit (approximately 25.5 pbb in FeNO group, 36.7 in 
controls). Disconcertingly, use of FeNO strategy did not result in a lower FeNO level at the 
end of trial. Moreover some of the algorithms utilised a safety-net to avoid excessively high 
doses of ICS in some participants whose FeNO remained high. Thirdly, as reported in risk of 
bias table (Table-2) obtaining accurate FeNO measurements at each visit could not be 
obtained, either due to a faulty analyser30 or technical issues.19 Also, many aspects need to be 
considered when analysing FeNO; this includes the timing of spirometry (transiently reduces 
FeNO), food and beverage, circadian rhythm, smoking history, ambient NO and exercise.43 
Lastly, FeNO values may not always reflect levels of airway eosinophilia as shown in a RCT 
using mepoluzimab .42   
 
Limitations of review 
This systematic review is limited to 22 studies with 3208 subjects completing the trials. While 
the studies share some common issues, there are also substantial differences, notably, the 
definition of asthma exacerbation, the participants, how the decision to prescribe oral steroids 
was made, the cut-off levels for FeNO and sputum eosinophils were different, the control 
strategies (that often used uses multiple measures) and how medications were adjusted. Also, 
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7 of the 16 FeNO-based studies were supported by the FeNO manufacturers and although we 
are unaware of any publication bias, we cannot be certain of its existence.  
 
CONCLUSION 
Tailoring of asthma therapy based on FeNO or sputum eosinophils has been shown to be 
effective in decreasing asthma exacerbations in adults. Adjusting treatment based on FeNO 
levels for children tended to decrease asthma exacerbations at the expense of increased ICS 
doses. At present, despite their popularity, there is insufficient evidence to advocate their use 
in routine clinical practice.  
 
Further, data starting with meta-analyses based on individual patient data (IPD) of all the 
studies may further inform the efficacy of strategies based on airway eosinophilic markers. If 
IPD meta-analysis does not shed more light e.g. the change in FeNO before medications are 
adjusted, further RCTs in both adults and children are then required. Ideally, these RCTs 
should include stratification e.g. high versus low doses of ICS, and eosinophilic versus non-
eosinophilic asthma and cost effectiveness.  
 
Figure Legend: 
Figure 1: PRISMA flow chart 
Figure 2: Number of subjects who had ≥1 exacerbation over study period (FeNO) 
Figure 3: Number of subject who had ≥1 exacerbation over study period (SpEos) 
Figure 4: Inhaled corticosteroid dose at final visit (FeNO) 
Figure 5: Risk of bias summary 
Supplement Figure 1: Mean dose of inhaled corticosteroid per person per day (SpEos) 
Supplement Figure 2: Symptom score as per ACT (FeNO) 
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Supplement Figure 3: Quality of life score (FeNO) 
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Study Sample size Participant Age Description of intervention 
and control arms  
Primary Outcome and 
definition of exacerbation 
Duration Funding and 
support 
Calhoun 
201235 
342 
randomised; 
FeNO group 
N=115. 
Control 
group 
N=114. 
FeNO group: 
mean age 35(SD 
11), 33 males. 
Control group: 
mean age 34 
(SD12), 42 
males.  
Control group: Treatment 
decisions based on National 
Heart, Lung and Blood 
Institute guidelines. 
 
FeNO group:  
<22ppb treatment stepped 
down 
22 to 35 maintain treatment 
>35 increase treatment 
Primary outcomes: Time to 
first treatment failure, a 
clinically important worsening 
of asthma 
 
Exacerbation: Increased 
asthma symptoms resulting in 
use of oral corticosteroids, 
increased ICS, or additional 
asthma medications. 
Participants 
were seen at 
week 2, 4, 6 and 
then every 6 
weeks for 9 
months. 
Follow-up 
duration: 9 
months 
National Institutes of 
Health and by 
National Institutes of 
Health Grants 
awarded by the 
National Heart, 
Lung, and Blood 
Institute 
Teva 
Pharmaceuticals 
provided the study 
drug and matching 
placebo. 
 
Cao 
200722 
41 
randomised; 
EOS strategy 
N=20. 
Control 
group N=21. 
EOS strategy: 
age 41 (SD2), 
11 males. 
Control group: 
age 43 (SD4), 
11 males. 
Control strategy: “Standard 
clinical guidelines” 
 
EOS strategy: decrease ICS 
if <1% eosinophils, keep 
ICS the same if 1-3% 
eosinophils, increase ICS if 
eosinophils >3%. 
Primary outcome: Total 
number of acute exacerbations. 
 
Exacerbation: Unknown 
Participants had 
a 2 week run-in, 
then visits at 
months 2, 4 and 
6. 
Follow-up 
duration: 6 
months 
Capital Medical 
Development 
Foundation (No. 
2002-3004) 
 
Chlumsky 
200623 
55 
randomised; 
EOS strategy 
N=30. 
Standard 
strategy 
N=25. 
EOS strategy: 
mean age 42(SD 
19) 13 males 
Standard 
strategy: mean 
age 48 (SD 16) 
Standard strategy arm: 
GINA guidelines 
EOS strategy: decrease ICS 
if ≤3%, keep same if 4-8%, 
increase ICS if ≥8%. 
 
 
Primary outcome: Rate of 
asthma exacerbations 
 
Exacerbation: a doubling of the 
frequency of symptoms or 
number of puffs of rescue 
salbutamol or a reduction in 
morning PEF by 30% or more 
on at least two consecutive 
days or two of the 
aforementioned or all three. 
Participants 
were assessed 
every 3 months 
for 18 months 
Internal Grant 
Agency of the 
Ministry of Health of 
the Czech Republic 
(Grant No. 5866/3) 
 
deJongste 
200930 
151 children 
randomised; 
FeNO group 
N=75. 
Symptom 
group N=72. 
FeNO group: 
mean age 11.6 
(SD 2.6), 46 
males.  
Symptom group: 
mean age 11.8 
(SD 4.3), 54 
males. 
All participants scored 
asthma symptoms in an 
electronic diary over 30 
weeks.  
FeNO group received a 
portable nitric oxide 
analyser. Aim to keep FeNo 
<20ppb 
 
Symptom group based on 
symptom score: Below 
range (< 10) = step 
down/discontinue, range 10 
to 60 = no change and range 
> 60 = step up 
 
Primary outcome: Proportion 
of symptom free days over the 
last 12 study weeks. 
 
Exacerbation: emergency visit, 
hospitalization or prednisolone 
course 
Children were 
seen at 3, 12, 21 
and 30 weeks.  
Groups had their 
medications 
changed every 3 
weeks based on 
electronic diary 
and/or FeNO 
levels. 
Follow-up 
duration = 30 
weeks. 
The study was 
supported by 
Aerocrine AB, 
Sweden. 
 
Fleming 
201226 
55 children 
randomised; 
Inflammatory 
group: median 
age 13.4 yrs 
Symptom group: Based on 
number of major 
exacerbations in the 
Primary outcome: Rate of 
major exacerbations and 
asthma control as assessed by 
Children were 
seen 3 monthly 
for 12 months. 
British Lung 
Foundation 
Inflammatory 
group N=27. 
Symptom 
group N=28. 
(range 11-15.8), 
16 males. 
Symptom group: 
median age 
12.6yrs (range 
10.2-14.7), 13 
males. 
preceding 3 months and 
SABA use in preceding 2 
weeks. 
 
Inflammatory group: 
Treatment aimed to keep 
sputum eosinophil counts 
<2.5%. 
symptom-free days and SABA 
use. 
 
Minor exacerbation: Use of 
bronchodilators >5 times/wk 
(excl. routine or pre-exercise). 
Major exacerbation: 
Deterioration requiring high 
dose oral corticosteroids (≥20 
mg/day) for at least 2 days. 
 
 
Fritsch 
200619 
52 patients 
entered the 
study; 
FeNO group 
N=22. 
Control 
group N=25. 
FeNO group: 
mean age 11.3 
(SD 3.4), 14 
males. 
Control group: 
mean age 12.1 
(SD 2.8), 14 
males. 
FeNO group: therapy was 
based on symptoms, beta-
agonists use, lung function 
and FeNO. 
Control group: therapy 
based on symptoms, beta-
agonists and lung function 
only. 
Primary outcome: FEV1 
 
Exacerbation defined by 4 
parameters: oral steroid 
courses, and/or off-scheduled 
visit because of asthma 
symptoms over the past 4 
weeks, and/or increase of 
asthma symptoms from a 
symptom score 0 or 1 to a 
symptom score 2 and/or 
decline of FEV1 (L) more than 
10% compared to the previous 
visit. 
 
Visits were at 6, 
12, 18 and 24 
weeks after 4 
week run-in. 
Follow-up 
duration = 24 
months. 
Aerocrine (analyser 
manufacturer) 
assisted with data 
analysis. 
 
Green 
200224  
74 
randomised; 
Sputum 
management 
group N=37. 
BTS 
Sputum 
management 
group: median 
age 50, range 
19-73, 19 males. 
Sputum management group: 
anti-inflammatory treatment 
was based on maintenance 
of sputum eosinophil count 
below 3% with a minimum 
1.Number of severe asthma 
exacerbations 
2.Control of eosinophilic 
airway inflammation measured 
by the induced sputum 
eosinophil count 
Study duration 
was for 12 
months with 
visits at month 
1, 2, 3, 4, 6, 8, 
10, 12. 
Trent NHS Regional 
Research Scheme. 
 
management 
group N=37. 
BTS 
management 
group: median 
age 47, range 
20-75, 21 males. 
dose of anti-inflammatory 
treatment. 
BTS management group: 
treatment decisions were 
based on traditional 
assessments of symptoms, 
peak expiratory flow and 
use of beta-2-agonists. 
3.Exhaled nitric oxide 
concentrations 
4.Symptom scores (0 to 3 for 
daytime and nighttime 
symptoms) 
5.Total asthma quality of life 
scores 
6.Peak flow amplitude as a 
proportion of the mean 
7.FEV1 
8.Changes from baseline of 
methacholine PC20 
9.Drug use 
10.Admissions for asthma 
Severe exacerbations defined 
as a decrease in morning peak 
expiratory flow to more than 
30% below baseline value on = 
2 consecutive days, or 
deterioration in symptoms 
needing rescue course of oral 
corticosteroid. 
 
Follow-up 
duration = 12 
months. 
Hashimoto 
201136 
95 adults 
were 
randomised; 
Internet 
strategy 
N=51. 
Conventional 
strategy 
N=38. 
Internet 
strategy: mean 
age 48.5 yrs 
(SD12.5), 23 
males. 
Conventional 
strategy: mean 
age 52.4 yrs 
Internet strategy: Had 
steroid dose adjusted based 
on the 3 components: 
electronic diary, in-built 
algorithm (which includes 
FeNO levels), and 
monitoring support, e.g. 
coaching by study nurse and 
Primary outcomes: Cumulative 
sparing OCS (actual 
cumulative dose minus the 
expected dose), ACT, and 
AQLQ. 
Exacerbations: Decrease in 
morning FEV1 >10% 
compared to mean FEV1 from 
week before, increase in 
Monthly visits 
with follow-up 
duration of 6 
months. 
Participants 
daily registered 
their dose of 
OCS, lung 
Netherlands 
Organisation for 
Health Research and 
Development 
(ZonMw). 
Equipment for the 
analysis of nitric 
(SD11.7), 18 
males. 
monitoring data, which was 
entered. 
Conventional strategy: 
GINA guidelines for the 
treatment of severe asthma. 
symptoms requiring increased 
prednisolone >10mg/day, or 
course of antibiotics, regardless 
of hospitalisations. 
function and 
FEV1. 
oxide was provided 
by Aerocrine AB.  
 
Honkoop 
201437 
GP practices 
cluster 
randomisatio
n including 
647 adults in 
3 arms; 
FeNO group 
N=189. 
Controlled 
asthma group 
N=203. 
 
FeNO group: 
mean age 39 yrs 
(SD 9), 62 
males. 
Control group: 
mean age 40 yrs 
(SD 10), 69 
males. 
FeNO strategy: Treatment 
targeted to keep FeNO 
<50ppb. 
Symptom strategy: ACT 
utilized including lung 
function 
Primary outcomes: Societal 
costs per QALY gained 
 
Severe exacerbation: 
Hospitalisation, emergency 
department visit because of 
asthma, or use of OCS for >3 
days. 
Follow-up 
duration of 12 
months with 3 
monthly visits. 
Netherlands 
Organisation for 
Health Research and 
Development and by 
the Netherlands 
Asthma Foundation. 
Aerocrine (Solna, 
Sweden) provided 
20 of a total of 40 
fraction of exhaled 
nitric oxide meters 
for free. 
Jayaram 
200631 
117 
randomised; 
Sputum 
strategy 
group N=50. 
Clinical  
strategy 
group N=52. 
Sputum 
strategy: group 
mean age 46 
(SD 13.8), 15 
males 
Clinical 
strategy: group 
mean age 43.5 
(SD 13.9), 15 
males 
Sputum strategy: dose of 
inhaled steroid was guided 
solely by induced sputum 
eosinophils to keep <2%. 
Spirometry was used to 
identify clinical control, 
exacerbations and other 
treatment. 
Clinical strategy: guided by 
symptoms as per Canadian 
Asthma Consensus Group 
Guidelines. 
1.Relative risk reduction for 
the first exacerbation 
2.The length of time without 
exacerbations 
3.Type and severity of 
exacerbations 
4. The usefulness of 
monitoring sputum cell counts 
in relation to the overall 
serverity of asthma. Defined by 
the minimum dose of inhaled 
steroid to maintain control 
2 year study 
duration with 
monthly visits in 
Phase 1 until 
control 
maintained with 
minimum 
treatment 
(variable 
duration) or at 
exacerbations. 
Phase 2: 3 
monthly visits or 
at exacerbations. 
Canadian Institutes 
of Health Research 
Clinical Trials Grant. 
 
5. The cumulative dose of 
inhaled steroid needed in Phase 
2 adjusted for its duration. 
 
Exacerbation: Loss of 
symptomatic control requiring 
increased use of short acting 
beta2-agonists by = 4 extra 
puffs per day for a minimum of 
48 hours, or by nocturnal 
symptoms, or early morning 
wakening due to respiratory 
symptoms two or more times 
in one week. Severe 
exacerbations were defined as 
requiring rescue courses of oral 
prednisone as defined by the 
investigator. 
 
Malerba 
201525 
28 adults 
randomised; 
Sputum 
strategy 
N=14. 
Clinical 
strategy 
N=14. 
Sputum 
strategy:  mean 
age 45.2 yrs 
(SD31.2), 5 
males. 
Clinical 
strategy: mean 
age 46.7 yrs 
(SD30.1), 6 
males. 
Sputum strategy: Treatment 
based on sputum eosinophil 
(%) and FeNO (ppb). 
Decrease ICS <2% & 
≤10pbb 
Keep same 2-3% & 11-
20ppb 
Increase ICS >3% & 
≥20ppb 
Symptom strategy: 
Symptom scores, use of 
SABA and night time 
symptoms. 
Primary outcome: Asthma 
exacerbations combined with 
changes in symptom score at 
end of study. 
 
Moderate exacerbations: 
Requiring an unscheduled visit 
with a course of OCS. 
Severe exacerbation: Course of 
OCS as determined by study 
investigator. 
Follow-up 
duration was 24 
months, with 6 
monthly visits.  
University of 
Brescia 
 
Peirsman 
201434 
99 children 
randomised; 
FeNO group 
N=49. 
Control 
group N=50. 
FeNO group: 
mean age 10.6 
yrs (SD 2.2), 33 
boys. 
Control group: 
mean age 10.7 
yrs (SD 2.1), 33 
boys. 
FeNO group: Treatment 
aimed to keep FeNO below 
20ppb. 
 
Control group: Treatment 
adjusted according to GINA 
guidelines (i.e. reporting of 
symptoms, use of SABA 
and FEV1) 
Primary outcome: Symptom 
free days using the first 4 
questions from childhood 
ACT. 
 
Exacerbation: As per GINA 
guidelines 
Follow-up 
duration was 12 
months with 3 
monthly 
appointments. 
Study funded 
partially by Merck & 
Co and FeNO 
analysers supplied 
by Aerocrine. 
 
Petsky 
201528 
63 
randomised; 
FeNO group 
N=31. 
Symptom 
group N=32. 
FeNO group: 
median age 10.2 
yrs (IQR 6.6 to 
12.7), 18 boys. 
Symptom group: 
median age 10.1 
yrs (IQR 6.3 to 
12.4), 13 boys.  
FeNO group: Treatment 
adjusted based on FeNO 
level and atopy status. 
Elevated FeNO defined as: 
≥ 10ppb with no positive 
SPT 
≥ 12ppb with 1 positive SPT 
≥ 20ppb with ≥ 2 positive 
SPT 
 
 
Primary outcome: Severe 
exacerbations requiring course 
of OCS with or without 
hospitalization. 
 
Exacerbation: Respiratory 
events requiring OCS. 
Study duration 
12 months with 
visits month 1, 
2, 3, 4, 6, 8, 10 
and 12. 
Asthma Foundation 
of Queensland 
Pijnenburg 
200518 
89 children 
randomised; 
FeNO group 
N=39 
Symptom 
group N=46 
FeNO group: 
median age 11.9 
(SD 2.9), 25 
males. 
Symptom group: 
mean age 12.6 
(SD 2.8), 30 
males. 
FeNO group: FeNO guided 
ICS dosing according to 
predetermined algorithm. 
Symptom group: Symptom 
scores influenced ICS 
dosing. 
Primary outcome: cumulative 
steroid dose (sum of mean 
daily steroid doses of visits 1 to 
5) 
 
Exacerbation: Deterioration in 
symptoms requiring oral 
prednisone course. 
 
Study duration 
was 12 months 
with 3 monthly 
visits. 
Kroger 
Foundation/Sophia 
Children’s Hospital 
Foundation 
Pike 
201332 
90 children 
randomised; 
FeNO group 
N=44. 
Standard 
management 
group N=46. 
FeNO group: 
mean age 10.51 
yrs (SD 2.62), 
21 boys. 
Standard 
management 
group: mean age 
11.42 yrs (SD 
2.69), 30 boys. 
 
FeNO group: FeNO 
measurements and symptom 
control. 
Standard management 
group: symptom control as 
per blinded clinician 
(reliever use, FEV1). 
 
Change in ICS dose, 
exacerbation frequency, FeNO 
measurements and lung 
function. 
 
Study duration 
12 months with 
study visits 
every 2 months. 
 
Sparks 
Powell 
201127 
220 pregnant 
women 
randomised; 
FeNO group 
N=111. 
Control 
group 
N=109. 
FeNO group: 
mean age 28 
(range 27 to 29). 
Control group: 
mean age 29 
(range 28 to 30). 
 
FeNO group: Sequential 
process, first FeNO 
concentrations used to 
adjust ICS dose, and second 
ACT score used to adjust 
the LABA dose. 
Clinical group: Based on 
asthma control using 
Juniper ACT with cutoff 
points defined as: well-
controlled asthma (ACT < 
0.75), partially controlled 
asthma (0.75 to 1.50), and 
uncontrolled asthma (> 1.5) 
 
Primary outcome: Total 
number of asthma 
exacerbations (i.e. moderate 
and severe). 
Secondary outcomes: QoL, 
asthma treatment, and fetal 
outcomes 
 
Study duration 
was average of 4 
months. Women 
were seen 
monthly until 
they delivered. 
National Health and 
Medical Research 
Council of Australia 
 
Shaw 
200738  
118 adults 
were 
randomised; 
FeNO group: 
median age 50 
FeNO group: FeNO 
>26ppb, ICS was increased. 
If FeNO <16ppb or <26ppb 
Primary outcome: Number of 
exacerbations 
 
Study duration 
was 12 months 
with participants 
Asthma UK 
 
FeNO group 
N=58 
Control 
group N=60. 
(range 20-75), 
27 males. 
Control group: 
median age 52 
(range 24-81), 
27 males. 
on 2 separate occasions, 
treatment was decreased. 
In Control Group treatment 
was doubled if Juniper 
Asthma Control Score 
(JACS) >1.57 and treatment 
halved if JACS <1.57 for 2 
consecutive months. 
Exacerbation: An increase in 
symptoms requiring oral 
steroids or antibiotics 
being send at 
baseline, 2 
weeks, months 
1, 2, 3, 4, 6, 8, 
10 and 12. 
Smith 
200521  
97 patients 
randomised 
from 110 
patients 
recruited. 
N=46 in FeNO 
group achieved 
optimal dose in 
phase 1 and 
N=28 achieved 
optimal dose in 
control group. 
Mean age of 
randomised 
patients was 
44.8 (range 12-
73), 41 males. 
Phase 1: Run-in period was 
for 6 weeks, after 2 weeks 
fluticasone 750ug/day was 
commenced. Visits were 
every 4 weeks until optimal 
dose was achieved. 
FeNO group: adjustment of 
dose of ICS was based soley 
to keep FeNO <15ppb at 
250mL/sec. 
Control group: dose 
adjustment based on asthma 
symptoms, night-time 
waking, bronchodilator use, 
variation in PEFR and 
FEV1. 
Phase 2: visits every 2 
months with upward 
adjustments made as per 
phase 1 but no downward 
adjustments would be made 
from optimal dose. 
Primary outcome: Frequency 
of exacerbation 
 
Minor exacerbation was 
defined as a daily asthma score 
of 2 or more on 2 or more 
consecutive days, whereas a 
major exacerbation was a daily 
asthma score of 3 or more on 2 
or more consecutive days. 
2 phase study, 
with phase 1 
varying in 
duration (3-12 
months) 
depending when 
optimal dose 
was deemed to 
have been 
achieved. 
During phase 2 
(12 months) 
optimal dose 
from phase 1 
was continued 
and therapy 
stepped up if 
asthma control 
was lost. 
Otago Medical 
Research 
Foundation, the 
Dean’s Fund of the 
Dunedin School of 
Medicine, and a 
grant from the 
University of Otago. 
Supplies of 
fluticasone were 
provided by 
GlaxoSmithKline 
(New Zealand). 
Equipment for the 
analysis of nitric 
oxide in other 
studies was provided 
by Aerocrine. 
 
Syk 
201339 
187 adults 
randomised; 
FeNO group 
N=87. 
Control 
group N=78. 
FeNO group: 
mean age 40.9 
yrs (SD 11.8), 
48 males. 
Control group: 
mean age 41.1 
yrs (SD 12.9), 
46 males. 
FeNO group: Keep FeNO 
level <24ppb for women, 
and <26ppb for men. 
Control group: Treatment 
adjusted based on patient 
reported symptoms, SABA 
use, physical examination 
and spirometry results. 
Primary outcome: change in 
mAQLQ score during the 
study. 
 
Exacerbation: Increasing 
asthma symptoms requiring 
course of OCS. 
Study duration 
was 12 months 
with visits at 
months 1, 2, 4, 8 
& 12. 
Stockholm county 
council (PickUP), 
Centre for Allergy 
Research, 
Karolinska Institute, 
and the Research 
Foundation of the 
Swedish Asthma and 
Allergy Association. 
Aerocrine AB 
(NIOX MINO 
instruments), Phadia 
AB (ImmunoCAP 
Rapid), Meda AB 
(Buventol 
Easyhaler), and 
MSD Sweden (small 
grant). 
 
Szefler 
200829 
546 
participants 
randomised 
from 780 
patients 
screened. 
FeNO group 
N=276. 
Control 
group N=270 
FeNO group: 
mean age 14.4, 
146 males. 
Control group: 
mean age 14.4, 
142 males. 
FeNO group: Standard 
treatment modified on the 
basis of measurements of 
FeNO 
Control group: Standard 
treatment based on the 
guidelines of National 
Asthma Education and 
Prevention Program 
(NAEPP). 
Primary outcome: Number of 
days with asthma symptoms. 
 
Exacerbation: Combination of 
admissions to hospital, 
unscheduled visits and oral 
prednisone. 
 
The study 
duration was 46 
weeks with 
visits every 6-8 
weeks. 
US National Institute 
of Allergy and 
Infectious Diseases, 
US National 
Institutes of Health. 
 Verini 
201020 
64 children 
randomised; 
FeNO group 
N=32. GINA 
group N=32. 
FeNO group: 
mean age 10.7 
yrs (SD 2.4), 18 
boys. 
GINA group: 
mean age 11.3 
yrs (SD 2.1), 18 
boys. 
FeNO group at 6 month 
visit only: step treatment up 
if >12ppb. 
Control group: As per 
GINA guidelines. 
Primary outcome: No clear 
definition given of outcomes, 
however asthma severity score, 
asthma exacerbation frequency 
and asthma therapy score were 
the main items reported in 
results section. 
 
Exacerbation: According to 
ATS/ERS criteria and 
requiring SABA. 
Study duration 
was 12 months 
with 6 monthly 
visits. 
No information 
provided on funding 
Voorend-
van 
Bergen 
201533 
272 children 
randomised 
into 3 arms; 
FeNO group 
N=92. 
Standard care 
group N=89.  
FeNO group: 
mean age 10.3 
yrs (SD 2.9), 62 
boys. 
Standard care 
group: mean age 
10.2 yrs (SD 
3.2), 61 boys. 
FeNO group: Treatment 
adjusted according to FeNO 
levels and ACT results. If 
ACT ≥ 20 and: 
FeNO < 25 = step down 
FeNO ≥ 25 to < 50 = no 
change 
FeNO ≥ 50 = step up 
If ACT < 20 and: 
FeNO ≥ 25 = step up 
FeNO < 25 = no change 
 
Control group: Treatment 
adjusted based on ACT 
results 
< 20 = step up 
≥ 20 = no change or step 
down 
 
Primary outcome: Changes 
from baseline of proportion of 
symptom-free days 
 
Exacerbation: No definition 
provided but OCS courses and 
hospitalization data included in 
the exacerbation results. 
Children were 
run-in for 4 
weeks, then 4 
monthly visits 
for a total of 12 
months. 
Lung Foundation 
Netherlands, the 
Netherlands 
Organisation for 
Health Research 
(ZonMW) and Fund 
Nuts Ohra. 



